Table 1 Demographic and preoperative characteristics of the 70 patients with rectal cancer and synchronous liver metastases according to their surgical management

N (%)

70 (100)

48 (69)

22 (31)

22 (50)

22 (50)

Age (years), median ± IQR

64 (54–68)

61 (54–67)

65 (60–77)

0.0644

59 (52–65)

65 (60–77)

0.012

≥ 60 years, n (%)

46 (65.7)

28 (58.3)

18 (81.8)

0.0634

11 (50)

18 (81.8)

0.026

< 60 years, n (%)

24 (34.3)

20 (41.7)

4 (18.2)

11 (50)

4 (18.2)

Sex ratio (female/male)

15/55

13/35

2/20

0.1208

8/14

2/20

0.021

BMI (kg/m²), median ± IQR

25.4 (23–28)

25.6 (23–28.8)

24.8 (23.4–27.2)

0.0244

24.4 (22.9–26.7)

24.8 (23.2–27.5)

0.740

ASA score, n (%)

1

25 (35.7)

14 (29.2)

11 (50)

0.2342

8 (36.4)

9 (40.9)

0.155

2

40 (57.2)

30 (62.5)

10 (45.5)

14 (63.6)

10 (45.5)

3

5 (7.1)

4 (8.3)

1 (4.5)

0

3 (13.6)

Arteriopathy, n (%)

2 (2.9)

2 (4.2)

0

1.0000

1 (4.6)

0

0.312

Diabetes, n (%)

11 (15.7)

9 (18.8)

2 (2.9)

0.4825

3 (13.6)

2 (9.1)

0.635

Tumor diagnosis, n (%)

Bleeding

38 (54.2)

23 (48)

15 (68.1)

0.1300

10 (45.5)

15 (68.2)

0.128

Weight loss

11 (15.7)

6 (12.5)

5 (22.7)

0,3035

4 (18.2)

5 (22.7)

0.709

Rectal adenocarcinoma location, n (%)

Upper (10–15 cm)

21 (30)

14 (29.2)

7 (31.8)

0,6572

3 (13.6)

6 (27.3)

0.449

Mid (5–10 cm)

28 (40)

18 (37.5)

10 (45.5)

10 (45.5)

10 (45.5)

Low (2–5 cm)

21 (30)

16 (33.3)

5 (22.7)

9 (40.9)

6 (27.3)

T stage, n (%)

T1

5 (7.1)

2 (4.2)

3 (13.7)

0.4345

0

3 (13.6)

0.283

T2

6 (8.6)

5 (10.4)

1 (4.5)

2 (9.1)

1 (4.6)

T3

51 (72.9)

36 (75)

15 (68.1)

18 (81.8)

15 (68.2)

T4

8 (11.4)

5 (10.4)

3 (13.7)

2 (9.1)

3 (13.6)

Liver metastasis

Bilobar (n, %)

34 (48.6)

25 (35.7)

9 (41)

0.4442

13 (59.1)

9 (40.9)

0.228

Number patients > 3 metastasis

19 (27.1)

15 (31.3)

4 (18.1)

0.3860

7 (31.8)

4 (18.2)

0.296

Number of metastasis (median, IQR)

2 (1–4)

3 (1–4)

2 (1–2)

0.7100

3 (1–4)

2 (1–3)

0.226

Neoadjuvant chemotherapy, n (%)

52 (74.3)

36 (75)

16 (72.7)

1.0000

17 (77.3)

19 (86.4)

0.434

Portal embolization, n (%)

6 (8.6)

3 (6.3)

3 (13.6)

0.3699

1 (4.6)

3 (13.6)

0.294

Neoadjuvant radiation therapy, n (%)

Long-course radiotherapy *

16 (22.9)

11 (23)

5 (22.7)

1.0000

5 (22.7)

5 (22.7)

0.999

Short-course radiotherapy **

14 (20)

9 (18.8)

5 (22.7)

5 (22.7)

5 (22.7)